or
forgot password

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation


Phase 1
18 Years
75 Years
Open (Enrolling)
Both
Multiple Myeloma, Blood and Marrow Transplant (BMT)

Thank you

Trial Information

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation


Inclusion Criteria:

- Evidence of recurrent or persistent hematologic malignancy following
HLA matched allogeneic hematopoietic cell transplant

- eligible for DLI

- no evidence of GVHD

- stable immunosuppressive regimen

- adequate renal and liver function

Exclusion Criteria:- CML patients who have not received DLI, active infections

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the feasibility of expanding allogeneic cytokine induced killer cells suitable for clinical application using a continuous perfusion culture system.

Outcome Time Frame:

21 to 28days before infusion

Safety Issue:

Yes

Principal Investigator

Robert S Negrin

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT162

NCT ID:

NCT00185757

Start Date:

June 2004

Completion Date:

December 2012

Related Keywords:

  • Multiple Myeloma
  • Blood and Marrow Transplant (BMT)
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317